Helix Immuno-Oncology is a 100% subsidiary of the parent company – Helix BioPharma Corp. Helix is currently listed on the Toronto Stock Exchange (TSX) as "HBP”. Helix Immuno-Oncology with its registered office in Warsaw, completed the process of transformation from a limited liability company into a joint-stock company in 2017. This is the first step on the way to the company's debut on the Warsaw Stock Exchange.
Helix Immuno-Oncology is actively working on the development of innovative products used in cancer therapy. The company's activities in development of potential drugs are based on the platform technology: Tumour Defense Breaker (DOS47), and in particular are focused on the V-DOS47 molecule, used in the treatment of breast cancer and other solid tumours.